|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
US5994391A
(en)
*
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6083497A
(en)
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
|
US6221897B1
(en)
|
1998-06-10 |
2001-04-24 |
Aventis Pharma Deutschland Gmbh |
Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
|
|
AU3103800A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
|
|
AU2003241629B2
(en)
*
|
1999-04-19 |
2005-06-16 |
Astrazeneca Ab |
An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
|
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2001068096A2
(en)
*
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
|
SE0003766D0
(sv)
*
|
2000-10-18 |
2000-10-18 |
Astrazeneca Ab |
Novel formulation
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002051396A1
(en)
*
|
2000-12-26 |
2002-07-04 |
Sankyo Company, Limited |
Pharmaceutical compositions containing cyclobutene derivatives
|
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
MY131995A
(en)
|
2001-09-08 |
2007-09-28 |
Astrazeneca Ab |
Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
|
|
CN1596240A
(zh)
|
2001-12-19 |
2005-03-16 |
阿特罗吉尼克斯公司 |
查耳酮衍生物及其治疗疾病的用途
|
|
WO2003053359A2
(en)
|
2001-12-19 |
2003-07-03 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
|
MXPA04006255A
(es)
|
2002-01-17 |
2004-09-27 |
Pharmacia Corp |
Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
|
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0213669D0
(en)
|
2002-06-14 |
2002-07-24 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2004020421A1
(ja)
*
|
2002-08-28 |
2004-03-11 |
Asahi Kasei Pharma Corporation |
新規な４級アンモニウム化合物
|
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
AU2005217318B2
(en)
|
2004-02-27 |
2010-07-01 |
Asahi Kasei Pharma Corporation |
Novel benzothiazepine and benzothiepine compounds
|
|
EP4137137A1
(en)
|
2010-05-26 |
2023-02-22 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
MX366925B
(es)
|
2010-11-04 |
2019-07-31 |
Albireo Ab |
Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
|
|
US20130236541A1
(en)
|
2010-11-08 |
2013-09-12 |
Albireo Ab |
Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
|
|
EA038594B1
(ru)
|
2011-10-28 |
2021-09-21 |
Шайр Хьюман Дженетик Терапис, Инк. |
Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
|
|
JP6217938B2
(ja)
|
2011-10-28 |
2017-10-25 |
ルメナ ファーマシューティカルズ エルエルシー |
小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
|
|
KR20160002773A
(ko)
|
2013-03-15 |
2016-01-08 |
루메나 파마수티컬즈, 인코포레이티드 |
원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
|
|
AU2014229050A1
(en)
|
2013-03-15 |
2015-10-22 |
Lumena Pharmaceuticals Llc |
Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
|
|
JO3301B1
(ar)
|
2013-04-26 |
2018-09-16 |
Albireo Ab |
تعديلات بلورية على إيلوبيكسيبات
|
|
CA2952406A1
(en)
|
2014-06-25 |
2015-12-30 |
Ea Pharma Co., Ltd. |
Solid formulation and method for preventing or reducing coloration thereof
|
|
CN106794188B
(zh)
|
2014-09-28 |
2022-12-02 |
华辉安健（北京）生物科技有限公司 |
聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
|
|
EP3012252A1
(en)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Crystal modifications of elobixibat
|
|
CN108601744B
(zh)
|
2016-02-09 |
2022-01-04 |
阿尔比里奥公司 |
口服考来烯胺制剂及其用途
|
|
JP6954927B2
(ja)
|
2016-02-09 |
2021-10-27 |
アルビレオ・アクチボラグ |
経口コレスチラミン製剤及びその使用
|
|
CA3011595C
(en)
|
2016-02-09 |
2024-01-02 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
|
CN111032019B
(zh)
|
2017-08-09 |
2022-07-05 |
阿尔比里奥公司 |
考来烯胺颗粒、口服考来烯胺制剂及其用途
|
|
JP7328207B2
(ja)
|
2017-08-09 |
2023-08-16 |
アルビレオ・アクチボラグ |
コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
|
|
SG11202001685TA
(en)
|
2017-08-28 |
2020-03-30 |
Enanta Pharm Inc |
Hepatitis b antiviral agents
|
|
JP7391048B2
(ja)
|
2018-06-05 |
2023-12-04 |
アルビレオ・アクチボラグ |
ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
KR20210024033A
(ko)
|
2018-06-20 |
2021-03-04 |
알비레오 에이비 |
오데빅시바트의 약학 제제
|
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
EP3883570A4
(en)
|
2018-11-21 |
2022-07-13 |
Enanta Pharmaceuticals, Inc. |
FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
|
|
CN113453753B
(zh)
|
2019-02-06 |
2024-07-23 |
阿尔比里奥公司 |
苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
|
|
SG11202108566VA
(en)
|
2019-02-06 |
2021-09-29 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
EP4424363B1
(en)
|
2019-02-12 |
2026-04-29 |
Mirum Pharmaceuticals, Inc. |
Methods for increasing growth in pediatric subjects having cholestatic liver disease
|
|
JP7665621B2
(ja)
|
2019-12-04 |
2025-04-21 |
アルビレオ・アクチボラグ |
ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
CA3158181A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
CA3158195A1
(en)
|
2019-12-04 |
2021-06-10 |
Per-Goran Gillberg |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
WO2021110885A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
CN114786772B
(zh)
|
2019-12-04 |
2024-04-09 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
ES3002777T3
(en)
|
2020-08-03 |
2025-03-07 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
AU2021379076A1
(en)
|
2020-11-12 |
2023-06-08 |
Albireo Ab |
Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
|
|
CN112274648B
(zh)
*
|
2020-11-23 |
2022-10-14 |
郑州大学 |
一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法
|
|
BR112023010799A2
(pt)
|
2020-12-04 |
2023-10-03 |
Albireo Ab |
Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
|
|
CN117412955A
(zh)
|
2021-06-03 |
2024-01-16 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
EP4536232A1
(en)
|
2022-06-09 |
2025-04-16 |
Albireo AB |
Treating hepatitis
|
|
TW202423921A
(zh)
*
|
2022-08-22 |
2024-06-16 |
美商安塔製藥公司 |
稠合的雜雙環抗病毒劑
|
|
WO2025146508A1
(en)
|
2024-01-05 |
2025-07-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
WO2025146507A1
(en)
|
2024-01-05 |
2025-07-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|